Objective - Development of new dosage forms with the ability to reside for long periods of time in the colon. The newly developed drug carriers will be of two types :- mucoadhesive polymeric carriers;- buoyant platforms. These are designed to deliver two classes of drugs : molecules aimed at local treatment of colon diseases and molecules susceptible to enzymatic degradation such as peptide drugs;- In vitro and in vivo studies in which the mucoadhesive polymers will be tested as to their ability to function successfully, i.e. adhere to mucosal tissues or float in physiologic fluids;- In vivo studies to test the viability of the hypothesis that prolongation of residence time in the colon can increase the bioavailability of enzyme susceptible drugs such as peptide drugs;- Development of an animal model (pig) in which in vivo studies will be performed validates the prolonged residence time of the drug carriers.Expected outcome- Localisation of anti-IBD drugs such as salicylate derivatives (5-amino salicylic adic) steroids with local action and hepatic clearance such as budesonide, immunosuppressive agents such as cyclosporine;- Early stages of colon cancer (when systemic prevention of possible metastasis in the blood comment is still not necessary);- GI absorption of highly lipophilic molecules;- GI absorption of peptide drugs or vaccines.Expected Outcome- Localisation of anti-IBD drugs such as salicylate derivatives (5-amino salicylic adic) steroids with local action and hepatic clearance such as budesonide, immunosuppressive agents such as cyclosporine;- Early stages of colon cancer (when systemic prevention of possible metastasis in the blood comment is still not necessary);- GI absorption of highly lipophilic molecules;- GI absorption of peptide drugs or vaccines.Activities- Polymers blends of Eudragit RL with Polycarbophil (acid form) in different ratios will be prepared and tested for physicochemical and mucoadhesion properties;- Fabrication of mucoadhesive drug delivery systems. The optimal polymer blends will be formulated into solid dosage forms and tested with two drug markers (at least one of which will be a protein drug) in rats for regional GI mucoadhesion;- New buoyant dosage forms will be prepared and tested in vitro and in vivo (dogs);- Novel delivery systems will be prepared and tested for selfbuoyancy properties in bench chemostat;- The novel formulations will be tested in pigs for increase in dosage form residence time using gamma scintigraphy;- Pilot human studies will conclude the research.- Polymers blends of Eudragit RL with Polycarbophil (acid form) in different ratios will be prepared and tested for physicochemical and mucoadhesion properties;- Fabrication of mucoadhesive drug delivery systems. The optimal polymer blends will be formulated into solid dosage forms and tested with two drug markers (at least one of which will be a protein drug) in rats for regional GI mucoadhesion;- New buoyant dosage forms will be prepared and tested in vitro and in vivo (dogs);- Novel delivery systems will be prepared and tested for selfbuoyancy properties in bench chemostat;- The novel formulations will be tested in pigs for increase in dosage form residence time using gamma scintigraphy;- Pilot human studies will conclude the research. Programme(s) IC-ISC C - Activity (Euratom, EEC) on cooperation in science and technology, 1984- Topic(s) Data not available Call for proposal Data not available Funding Scheme CSC - Cost-sharing contracts Coordinator University of Nottingham EU contribution No data Address University Park NG7 2RD Nottingham United Kingdom See on map Total cost No data
